Antibiotics and collateral damage

Clinical Cornerstone

Volumn 6, Issue SPEC. ISS APR., 2004, Pages 12-20

  Hoban, Daryl J ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BETA LACTAM ANTIBIOTIC; CEFOXITIN; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DICLOXACILLIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIMENTIN; TROVAFLOXACIN; VANCOMYCIN;

ACUTE DIARRHEA; ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL FLORA; BACTERIAL OVERGROWTH; BACTERICIDAL ACTIVITY; BACTEROIDES FRAGILIS; BYSTANDER EFFECT; CLINICAL RESEARCH; CLOSTRIDIUM DIFFICILE; COMMENSALISM; ESCHERICHIA COLI; EXPERIMENTAL DESIGN; HUMAN; INTESTINE FLORA; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; RESPIRATORY TRACT INFECTION;

EID: 3042651498     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Marshall JC. Gastrointestinal flora and its alterations in critical illness. Curr Opin Clin Nutr Metab Care. 1999;2:405-411.
2. Gould IM. Antibiotic policies and control of resistance. Curr Opin Infect Dis. 2002;15:395-400.
3. Kariuki S, Hart CA. Global aspects of antimicrobial-resistant enteric bacteria. Curr Opin Infect Dis. 2001;14:579-586.
4. Andremont A. The future control of bacterial resistance to antimicrobial agents. Am J Infect Control. 2001;29:256-258.
5. Andersson MI, MacGowan AP. Development of the quinolones. J Antimicrob Chemother. 2003; 51(Suppl 1):1-11.
6. Emmerson AM, Jones AM. The quinolones: decades of development and use. J Antimicrob Chemother. 2003;51(Suppl 1):13-20.
7. Bartlett JG, Dowell SF, File TMJ, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis. 2000;31:347-382.
8. Lautenbach E, Larosa LA, Kasbekar N, et al. Fluoroquinolone utilization in the emergency departments of academic medical centers: prevalence of, and risk factors for, inappropriate use. Arch Intern Med. 2003;163:601-605.
9. Martin SJ, Jung R, Garvin CG. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections. Drug Saf. 2001;24:199-222.
10. Lautenbach E, Fishman NO, Bilker WB, et al. Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch Intern Med. 2002;162:2469-2477.
11. Davies TA, Goldschmidt R, Pfleger S, et al. Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000). J Antimicrob Chemother. 2003;52:168-175.
12. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Am J Respir Crit Care Med. 2001;163:1730-1754.
13. British Thoracic Society Standards of Care Committee. BTS guidelines for the management of community acquired pneumonia in adults. Thorax. 2001;56(Suppl 4):IV1-64.
14. Scheld WM. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis. 2003;9:1-9.
15. Zhanel GG, Ennis K, Vercaigne L, et al. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs. 2002;62:13-59.
16. Zhanel GG, et al. Presented at: The 102nd General Meeting of the American Society for Microbiology; May 19-23, 2002; Salt Lake City, Utah.
17. Dever LL, China C, Eng RH, et al. Vancomycin-resistant Enterococcus faecium in a Veterans Affairs medical center: association with antibiotic usage. Am J Infect Control. 1998;26:40-46.
18. Lautenbach E, LaRosa LA, Marr AM, et al. Changes in the prevalence of vancomycin-resistant enterococci in response to antimicrobial formulary interventions: impact of progressive restrictions on use of vancomycin and third-generation cephalosporins. Clin Infect Dis. 2003;36:440-446.
19. Avelox [package insert]. West Haven, Conn: Bayer Corporation; 2003.
20. Cipro [package insert]. West Haven, Conn: Bayer Corporation; 2003.
21. Levaquin [package insert]. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc; 2003.
22. Wilcox MH, Fawley W, Freeman J, et al. In vitro activity of new generation fluoroquinolones against genotypically distinct and indistinguishable Clostridium difficile isolates. J Antimicrob Chemother. 2000;46:551-556.
23. Donskey CJ, Chowdhry TK, Hecker MT, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med. 2000;343:1925-1932.
24. McFarland LV. Epidemiology of infectious and iatrogenic nosocomial diarrhea in a cohort of general medicine patients. Am J Infect Control. 1995; 23:295-305.
25. Khan R, Cheesbrough J. Impact of changes in antibiotic policy on Clostridium difficile-associated diarrhoea (CDAD) over a five-year period in a district general hospital. J Hosp Infect. 2003;54:104-108.
26. Rao Gopal G, Rao Mahankali CS, Starke I. Clostridium difficile-associated diarrhea in patients with community-acquired lower respiratory infection being treated with levofloxacin compared with β-lactam-based therapy. J Antimicrob Chemother. 2003;51:697-701.
27. Miller M, et al. Clostridium difficile-associated diarrhea and antimicrobial use. Presented at: The 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego, Calif.